ストックスクリーナーアプリを入手
28.65
15.25%
3.79
アフターアワーズ：
28.65
Tyra Biosciences Inc (TYRA) 最新ニュース
Tyra Biosciences downgraded to Hold ahead of ke... - Pluang
Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts - Seeking Alpha
TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout - Asianet Newsable
Tyra Bio rises on upcoming mid-stage trial data (TYRA:NASDAQ) - Seeking Alpha
Initial results for an oral bladder cancer drug will be discussed Sept. 9 - Stock Titan
Tyra Biosciences draws industry focus with IR NMIBC research at IBCG26 retreat - Traders Union
Tyra Biosciences (TYRA): Can Dabogratinib Redefine FGFR3-Driven Bladder Cancer? - RTTNews
Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - moomoo.com
Tyra (TYRA) Results Check: EPS Falls Short of Its Estimate in the Current Update; Post-Earnings: The Market Price Moves 0.65% Higher in the Latest ReadingFinancial Data - vinanet.vn
Tyra’s one-drug, three-indication bet nears its first phase 2 test - Pharma Voice
Farallon Capital Management Slashes Tyra Biosciences (TYRA) Stak - GuruFocus
Tyra Biosciences Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Tyra Biosciences tests innovative therapy in SURF302 for intermediate-risk bladder cancer - Traders Union
Tyra Biosciences (NASDAQ: TYRA): What Comes Next for Its Pipeline? - Kalkine Media
Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 6.2%Time to Buy? - MarketBeat
TYRA Q2 2026 Earnings: EPS Miss Slightly Overshadowed by 6.98% Share AdvanceBasic EPS Analysis - vinanet.vn
TYRA Q2 2026 Earnings: EPS Misses Estimates by 4.14% as Shares Gain 1.08%Healthcare Earnings Report - vinanet.vn
TYRA Q2 2026 Earnings: Wider-than-Expected Loss of -$0.69 per Share, Yet Stock Rises 1.08%Dividend Growth Analysis - vinanet.vn
Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA - MarketBeat
TYRA Biosciences (TYRA) holder reports 3.55M-share, 6% beneficial stake - Stock Titan
Tyra Biosciences examines FGFR3 gene impact on cell growth disorders - Traders Union
Farallon group trims Tyra Biosciences (TYRA) holdings to 6,000 shares, 0% stake - Stock Titan
Avoiding Lag: Real-Time Signals in (TYRA) Movement - Stock Traders Daily
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% Upside - TradingView
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $39 - Moomoo
BofA Adjusts Price Target on Tyra Bioscience to $39 From $42 - marketscreener.com
TYRA's dabogratinib trial in 2026 could validat... - Pluang
Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet (NASDAQ:TYRA) - Seeking Alpha
HC Wainwright Brokers Lower Earnings Estimates for TYRA - MarketBeat
Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TYRA Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Pipeline InvestmentFinancial Health Score - vinanet.vn
Tyra Biosciences (TYRA) Projected to Announce Earnings on Thursday - MarketBeat
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
BlackRock, Inc. Expands Tyra Biosciences (TYRA) Stake with Strat - GuruFocus
Jefferies Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42 - Moomoo
TYRA Shares Drop Amid Market Volatility; Price-to-Sales Highligh - GuruFocus
Wedbush Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $53 - Moomoo
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down Following Weak Earnings - marketbeat.com
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - Moomoo
Tyra Biosciences (NASDAQ:TYRA) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Tyra Biosciences : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Tyra Biosciences 2Q 2026: Net loss $45.6M, EPS $(0.69) — 10-Q Summary - TradingView
Tyra Biosciences Q2 net loss widens on higher R&D expenses - TradingView
Tyra Biosciences posts Q2 2026 net loss $45.6M; cash $353.9M, runway into 2H 2028 - TradingView
TYRA: Phase 2 trials progress, strong cash runway, and higher R&D drive increased net loss - TradingView
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights - PR Newswire
Tyra Biosciences to release initial Phase 2 dat... - Pluang
Arkadios Wealth Advisors Makes New $1.82 Million Investment in Tyra Biosciences, Inc. $TYRA - MarketBeat
Tyra Biosciences (TYRA) Edges Up to $32.15 as Biotech Sentiment SteadiesMotive Wave - vinanet.vn
Discipline and Rules-Based Execution in TYRA Response - Stock Traders Daily
Tyra Biosciences, Inc. $TYRA Stock Position Boosted by Seven Fleet Capital Management LP - MarketBeat
TYRA Q1 2026 Earnings: EPS Falls Short of Estimates as Clinical Pipeline Investment DeepensEarnings Miss Streak - vinanet.vn
Janus Henderson Group PLC Acquires 955,147 Shares of Tyra Biosciences, Inc. $TYRA - MarketBeat
BlackRock (TYRA holder) reports 2.98M TYRA Biosciences shares, a 5% passive stake - Stock Titan
Tyra Biosciences Advances TYRA-200 Into First-in-Human FGFR2 Cancer Trial - TipRanks
Tyra Biosciences Advances First‑in‑Human TYRA‑430 Trial in FGFR‑Driven Liver and Solid Tumors - TipRanks
Tyra Biosciences, Inc. $TYRA Shares Sold by Eversept Partners LP - MarketBeat
Tyra Biosciences Inc (TYRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tyra Biosciences Inc (TYRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tyra Biosciences Inc (TYRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Commodore Capital LP Lowers Stake in Tyra Biosciences, Inc. $TYRA - MarketBeat
TYRA|Tyra Biosciences Inc|Price:24.750|Chg%:-0.190 - TradingKey
Tyra Biosciences Inc (TYRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TYRA|Tyra Biosciences Inc|Price:26.510|Chg%:-0.450 - TradingKey
TradingKey - TradingKey
Tyra Biosciences, Inc. Revenue Breakdown – NASDAQ:TYRA - TradingView
Affinity Asset Advisors LLC Makes New $9.86 Million Investment in Tyra Biosciences, Inc. $TYRA - MarketBeat
Tyra Biosciences tests oral treatment aiming to lower management burden in NMIBC - Traders Union
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):